| Year |
Citation |
Score |
| 2019 |
Metcalf C, Svenson S, Hwang J, Tripathi S, Gangal G, Kabir S, Lazarus D, Cole R, Sweryda-Krawiec B, Shum P, Brown D, Case R, van der Poll D, Rohde E, Harlfinger S, ... ... Eliasof S, et al. Discovery of a Novel Cabazitaxel Nanoparticle-Drug Conjugate (CRLX522) with Improved Pharmacokinetic Properties and Anticancer Effects using a β-Cyclodextrin-PEG Copolymer-Based Delivery Platform. Journal of Medicinal Chemistry. PMID 31593466 DOI: 10.1021/acs.jmedchem.9b00892 |
0.367 |
|
| 2017 |
Chao J, Lin J, Frankel P, Clark AJ, Wiley DT, Garmey E, Fakih M, Lim D, Chung V, Luevanos E, Eliasof S, Davis ME, Yen Y. Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer. Journal of Gastrointestinal Oncology. 8: 962-969. PMID 29299355 DOI: 10.21037/Jgo.2017.08.10 |
0.39 |
|
| 2017 |
Rey S, Schito L, Wouters BG, Eliasof S, Kerbel RS. Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy. Trends in Cancer. 3: 529-541. PMID 28718406 DOI: 10.1016/J.Trecan.2017.05.002 |
0.322 |
|
| 2017 |
O'Connor LO, Wang AT, Jones D, Odedra R, Spreadborough M, Wilson J, Smith A, Cotton P, Reens J, Barnes J, Sheridan V, Tellez A, Lau A, Sadler C, O'Connor MJ, ... Eliasof S, et al. Abstract B32: CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, combined with DDR agents provides a novel approach to increasing therapeutic index Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-B32 |
0.402 |
|
| 2017 |
Metcalf C, Poll Dvd, Zhao L, Halo T, Lazarus D, Stockmann A, Peters C, Brown D, Case R, Rohde E, Jayaraman L, Wang H, Crowell T, Senderowicz A, Eliasof S. Abstract PR10: Significant improvements in therapeutic index for conjugated payloads using a nanoparticle-drug conjugate (NDC) platform to provide sustained drug release and potentially improved anticancer effects Cancer Research. 77. DOI: 10.1158/1538-7445.Epso16-Pr10 |
0.396 |
|
| 2017 |
Metcalf CA, Poll Dvd, Zhao L, Case RI, Lazarus D, Brown D, Halo T, Jayaraman L, Peters C, Rohde E, Eliasof S. Abstract 5135: Sustained and controlledin vivotherapeutic levels of drug payloads in tumors using two separate drug combination platforms: Antibody nanoparticle-drug conjugates and multi-drug nanoparticle-drug conjugates, with the potential for improved drug combinability and anticancer effects Cancer Research. 77: 5135-5135. DOI: 10.1158/1538-7445.Am2017-5135 |
0.321 |
|
| 2016 |
Tian X, Nguyen M, Foote HP, Caster JM, Roche KC, Peters CG, Wu P, Jayaraman L, Garmey EG, Tepper JE, Eliasof S, Wang AZ. CRLX101, a nanoparticle-drug conjugate containing camptothecin, improves rectal cancer chemoradiotherapy by inhibiting DNA repair and HIF-1α. Cancer Research. PMID 27784746 DOI: 10.1158/0008-5472.Can-15-2951 |
0.4 |
|
| 2016 |
Keefe SM, Hoffman-Censits J, Cohen RB, Mamtani R, Heitjan D, Eliasof S, Nixon A, Turnbull B, Garmey EG, Gunnarsson O, Waliki M, Ciconte J, Jayaraman L, Senderowicz A, Tellez AB, et al. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 27: 1579-85. PMID 27457310 DOI: 10.1093/Annonc/Mdw188 |
0.375 |
|
| 2016 |
Svenson S, Case RI, Cole RO, Hwang J, Kabir SR, Lazarus D, Lim Soo P, Ng PS, Peters C, Shum P, Sweryda-Krawiec B, Tripathi S, van der Poll D, Eliasof S. Tumor Selective Silencing Using an RNAi-Conjugated Polymeric Nanopharmaceutical. Molecular Pharmaceutics. PMID 26835715 DOI: 10.1021/acs.molpharmaceut.5b00608 |
0.363 |
|
| 2016 |
Chao J, Lin J, Frankel PH, Clark AJ, Wiley DT, Garmey EG, Fakih M, Lim D, Chung VM, Luevanos E, Eliasof S, Davis ME, Yen Y. Pilot trial of CRLX101 in patients (pts) with advanced, chemotherapy-refractory gastroesophageal cancer (GEC). Journal of Clinical Oncology. 34: 44-44. DOI: 10.1200/Jco.2016.34.4_Suppl.44 |
0.378 |
|
| 2016 |
Krasner C, Birrer M, Peters C, Jayaraman L, Eliasof S, Tellez A, Downing W, Senderowicz A. Abstract CT090: Phase II trial of the NDC CRLX101 in combination with bevacizumab in patients with platinum-resistant ovarian cancer (PROC) Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct090 |
0.329 |
|
| 2016 |
O’Connor LO, Wang AT, Jones DR, Odedra R, Spreadborough M, Wilson J, Smith A, Cotton P, Reens J, Barnes J, Sheridan V, Eliasof S, Tellez A, Lau A, Sadler C, et al. Abstract 3721: A camptothecin-containing nanoparticle-drug conjugate combination with DDR agents provides a novel approach to increasing therapeutic index Cancer Research. 76: 3721-3721. DOI: 10.1158/1538-7445.Am2016-3721 |
0.386 |
|
| 2016 |
Lazarus D, Peters C, Stockmann A, Eliasof S, Jayaraman L. Abstract 3209: CRLX101, an investigational nanoparticle-drug conjugate of camptothecin, demonstrates synergy with immunotherapy agents in preclinical models Cancer Research. 76: 3209-3209. DOI: 10.1158/1538-7445.Am2016-3209 |
0.38 |
|
| 2016 |
Zamboni WC, Markman B, Souza Pd, Dees EC, Gangadhar T, Eliasof S, Murphy C, Senderowicz A, Wang H. Abstract 2047: Pharmacokinetics (PK) of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing the payload docetaxel, in patients with refractory solid tumors Cancer Research. 76: 2047-2047. DOI: 10.1158/1538-7445.Am2016-2047 |
0.323 |
|
| 2016 |
Peters CG, Lazarus D, Brown D, Zhang N, Stockmann AP, Case R, Rohde E, Eliasof S, Jayaraman L. Abstract 1345: Tumor selective localization of CRLX101, an investigational nanoparticle-drug conjugate of camptothecin Cancer Research. 76: 1345-1345. DOI: 10.1158/1538-7445.Am2016-1345 |
0.401 |
|
| 2015 |
Conley SJ, Baker TL, Burnett JP, Theisen RL, Lazarus D, Peters CG, Clouthier SG, Eliasof S, Wicha MS. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Research and Treatment. 150: 559-67. PMID 25833208 DOI: 10.1007/s10549-015-3349-8 |
0.385 |
|
| 2015 |
Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 808-18. PMID 25524310 DOI: 10.1158/1078-0432.Ccr-14-2810 |
0.354 |
|
| 2015 |
Wang A, Tian X, Nguyen M, McRee AJ, Sanoff HK, O'Neil BH, Hennessy MG, Eliasof S, Garmey EG, Tepper JE. Improving neoadjuvant chemoradiotherapy for rectal cancer with CRLX101, a nanoparticle-drug conjugate, with a camptothecin payload. Journal of Clinical Oncology. 33: 645-645. DOI: 10.1200/Jco.2015.33.3_Suppl.645 |
0.393 |
|
| 2015 |
Krasner CN, Birrer MJ, Berlin ST, Buss MK, Eliasof S, Garmey EG, Hennessey M, Horowitz NS, Konstantinopoulos P, Matulonis UA. Targeting VEGFRi resistance through HIF-1á suppression: Phase II clinical trial evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent platinum resistant ovarian cancer. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps5614 |
0.385 |
|
| 2015 |
Keefe SM, Hoffman-Censits JH, Mamtani R, Walicki M, Robinson J, Smith A, Gunnarsson O, Piscitelli A, Hennessey M, Jayaraman L, Nixon AB, Eliasof S, Cohen RB, Vaughn DJ, Garmey EG, et al. HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev). Journal of Clinical Oncology. 33: 4543-4543. DOI: 10.1200/Jco.2015.33.15_Suppl.4543 |
0.364 |
|
| 2015 |
Tian X, Nguyen M, Foote H, Wagner KT, Sanoff HK, McRee AJ, O'Neil BH, Calvo BF, Blackstock WA, Tepper JE, Garmey E, Eliasof S, Wang AZ. Abstract 5515: Neoadjuvant chemoradiotherapy for rectal cancer with CRLX101, an investigational nanoparticle-drug conjugate with a camptothecin payload Cancer Research. 75: 5515-5515. DOI: 10.1158/1538-7445.Am2015-5515 |
0.402 |
|
| 2015 |
Pham E, Lee CR, Xu P, Man S, Yin M, Foster FS, Peters CG, Lazarus D, Eliasof S, Kerbel RS. Abstract 4124: Potent anti-tumor and metastatic breast cancer efficacy of bevacizumab with CRLX101, an investigational chemotherapy nanoparticle-drug conjugate that secondarily suppresses HIF-1α Cancer Research. 75: 4124-4124. DOI: 10.1158/1538-7445.Am2015-4124 |
0.396 |
|
| 2015 |
Conley SJ, Baker TL, Burnet JP, Thiesen RL, Lazarus D, Peters CG, Clouthier SG, Eliasof S, Wicha MS. Abstract 1384: CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, reverses the HIF-1α-mediated increase in cancer stem cells caused by bevacizumab in a preclinical model of triple-negative breast cancer Cancer Research. 75: 1384-1384. DOI: 10.1158/1538-7445.Am2015-1384 |
0.43 |
|
| 2015 |
Peters CG, Lazarus D, Brown D, Zhang N, Case R, Rohde E, Eliasof S, Jayaraman L. Abstract B37: Selective tumor localization of CRLX101, a novel nanoparticle-drug conjugate Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B37 |
0.406 |
|
| 2015 |
Clark A, Wiley DT, Zuckerman JE, Webster P, Chao J, Lin J, Yen Y, Davis ME, Eliasof S. Abstract B33: CRLX101, an investigational nanoparticle-drug conjugate, localizes in human tumors and not in adjacent healthy tissue after intravenous dosing Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B33 |
0.368 |
|
| 2015 |
Metcalf C, Brown D, Hwang J, Kabir S, Lazarus D, Shum P, Tripathi S, Eliasof S. Abstract B176: In vitro and in vivo studies demonstrating sustained drug release for multiple anticancer payloads and improved anticancer effects of a cabazitaxel β-cyclodextrin-PEG copolymer-based nanoparticle-drug conjugate (NDC) Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B176 |
0.348 |
|
| 2014 |
Eblan MJ, Sanoff HK, McRee AJ, O'Neil BH, Garmey EG, Hennessy MG, Eliasof S, Tepper JE, Wang A. Phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps3667 |
0.359 |
|
| 2014 |
Keefe SM, Hennessey M, Robinson J, Mykulowicz K, Gunnarsson O, Mamtani R, Vaughn DJ, Hoffman-Censits JH, Nathanson KL, Pryma DA, Eliasof S, Garmey EG, Cohen RB, Haas NB. HIF inhibition in mRCC: Planned interim analysis of CRLX101 with bevacizumab (bev), a phase 1b/2a. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E15611 |
0.331 |
|
| 2014 |
Keefe SM, Hennessy M, Gunnarsson O, Mamtani R, Vaughn D, Hoffman-Censits J, Nathanson K, Lal P, Pryma D, Eliasof S, Garmey E, Cohen RB, Haas NB. Abstract CT340: Phase 1b/2a study of the nanopharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC): results from the planned interim analysis Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct340 |
0.348 |
|
| 2014 |
Lazarus D, Kabir S, Eliasof S. Abstract 4582: CRLX522, a novel dynamic tumor-targeted cabazitaxel nanopharmaceutical Cancer Research. 74: 4582-4582. DOI: 10.1158/1538-7445.Am2014-4582 |
0.365 |
|
| 2013 |
Lazarus D, Peters C, Deotale K, Eliasof S. Abstract 376: CRLX101, a nanopharmaceutical in phase 2 clinical trials, is synergistic with antiangiogenic treatment through HIF-1α inhibition in an ovarian cancer xenograft model. Cancer Research. 73: 376-376. DOI: 10.1158/1538-7445.Am2013-376 |
0.37 |
|
| 2013 |
Keefe SM, Cohen RB, Eliasof S, Garmey EG, Hennessy M, Mykulowicz KM, Pryma DA, Haas N. Abstract 2419: A phase Ib-IIa study evaluating the nanopharmaceutical CRLX101 in combination with bevacizumab in the treatment of patients (pts.) with advanced renal cell carcinoma. Cancer Research. 73: 2419-2419. DOI: 10.1158/1538-7445.Am2013-2419 |
0.404 |
|
| 2013 |
Eliasof S, Conley S, Keefe SM, Kerbel R, Krasner CN, Lazarus D, Peters C, Pham E, Wicha MS, Garmey EG. Abstract PR09: Synergistic activity of CRLX101, a nanopharmaceutical in Phase II clinical trials, with antiangiogenic therapies mediated through HIF-1alpha inhibition: A translational research program. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-Pr09 |
0.413 |
|
| 2012 |
Lazarus D, Kabir S, Eliasof S. Abstract 5643: CRLX301, a novel tumor-targeted taxane nanopharmaceutical Cancer Research. 72: 5643-5643. DOI: 10.1158/1538-7445.Am2012-5643 |
0.383 |
|
| 2011 |
Young C, Schluep T, Hwang J, Eliasof S. CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Camptothecin in Clinical Development. Current Bioactive Compounds. 7: 8-14. PMID 22081768 DOI: 10.2174/157340711795163866 |
0.308 |
|
| 2011 |
Svenson S, Wolfgang M, Hwang J, Ryan J, Eliasof S. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. Journal of Controlled Release : Official Journal of the Controlled Release Society. 153: 49-55. PMID 21406204 DOI: 10.1016/j.jconrel.2011.03.007 |
0.367 |
|
| 2011 |
Kabir SR, Lazarus D, Eliasof S. Abstract C38: CRLX101 shows significant tumor penetration and superior activity compared to first- and second-line agents in NSCLC xenograft tumor models. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C38 |
0.391 |
|
| 2001 |
Seal RP, Shigeri Y, Eliasof S, Leighton BH, Amara SG. Sulfhydryl modification of V449C in the glutamate transporter EAAT1 abolishes substrate transport but not the substrate-gated anion conductance. Proceedings of the National Academy of Sciences of the United States of America. 98: 15324-9. PMID 11752470 DOI: 10.1073/pnas.011400198 |
0.35 |
|
| 1998 |
Eliasof S, Arriza JL, Leighton BH, Amara SG, Kavanaugh MP. Localization and function of five glutamate transporters cloned from the salamander retina. Vision Research. 38: 1443-54. PMID 9667010 DOI: 10.1016/S0042-6989(97)00452-5 |
0.357 |
|
| 1998 |
Eliasof S, Arriza JL, Leighton BH, Kavanaugh MP, Amara SG. Excitatory amino acid transporters of the salamander retina: identification, localization, and function. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 698-712. PMID 9425012 DOI: 10.1523/Jneurosci.18-02-00698.1998 |
0.365 |
|
| 1997 |
Arriza JL, Eliasof S, Kavanaugh MP, Amara SG. Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proceedings of the National Academy of Sciences of the United States of America. 94: 4155-60. PMID 9108121 DOI: 10.1073/Pnas.94.8.4155 |
0.388 |
|
| 1997 |
Eliasof S, Jahr CE. Rapid AMPA receptor desensitization in catfish cone horizontal cells. Visual Neuroscience. 14: 13-8. PMID 9057264 DOI: 10.1017/S0952523800008713 |
0.61 |
|
| 1996 |
Eliasof S, Jahr CE. Retinal glial cell glutamate transporter is coupled to an anionic conductance. Proceedings of the National Academy of Sciences of the United States of America. 93: 4153-8. PMID 8633032 DOI: 10.1073/Pnas.93.9.4153 |
0.622 |
|
| 1993 |
Eliasof S, Werblin F. Characterization of the glutamate transporter in retinal cones of the tiger salamander. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 13: 402-11. PMID 8093715 DOI: 10.1523/Jneurosci.13-01-00402.1993 |
0.574 |
|
| 1988 |
Werblin F, Maguire G, Lukasiewicz P, Eliasof S, Wu SM. Neural interactions mediating the detection of motion in the retina of the tiger salamander. Visual Neuroscience. 1: 317-29. PMID 2856477 DOI: 10.1017/S0952523800001978 |
0.631 |
|
| 1987 |
Eliasof S, Barnes S, Werblin F. The interaction of ionic currents mediating single spike activity in retinal amacrine cells of the tiger salamander. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 7: 3512-24. PMID 3681403 DOI: 10.1523/Jneurosci.07-11-03512.1987 |
0.533 |
|
| Show low-probability matches. |